Double-Blind 0.2mg CBP-307 for Ulcerative Colitis

"Qualified candidates for this trial must be aged 18-75, have been diagnosed with an ulcer at least three months prior to screening, and demonstrate moderate to severe active UC based on the adapted Mayo score and endoscopic subscore. Additionally, they must use highly effective contraception during the study period as well as four weeks after their last dose of medication. Participants can also receive oral or IV corticosteroids before randomization if they have taken them continuously at a stable dosage for 4 weeks leading up to enrollment. Lastly, any concomitant medications used in the 7 days preceding first dose of investigational product must remain unchanged throughout the duration"

"This medical trial is accepting volunteers of legal age (18+) and below the maximum cut-off of 75 years old."

"This research study is not currently recruiting, as indicated by clinicaltrials.gov information; the trial was initially posted on February 27th 2019 and last modified April 20th 2022. Despite this, there are 397 other trials that have open enrollment right now."

"Presently, this research project is taking place at 14 locations. The trial sites are located in Homestead, Hialeah and Mission Hills as well as 11 other areas. To reduce the burden of travel associated with enrolling in a clinical trial, it may be wise to select the closest available location for participation."

"Our team's assessment of the safety profile of CBP-307 is a 2, given that this Phase 2 trial has collected evidence in support of its security but not yet on efficacy."